drugset

drugset / Trial / NCT00821977

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

NCT00821977 ↗

Phase 2/3 Completed 338 enrolled Novartis

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.

Timeline

Start: 2008-11
Primary completion: 2010-10
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vildagliptin	Other / unclassified	—	—

Indications